Contribution of Involved-field Radiotherapy to Survival in Patients With Relapsed or Refractory Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation
Authors:
- Leylagül KaynarLKLeylagül Kaynar
- Okan OrhanOOOkan Orhan
- Muzaffer KeklikMKMuzaffer Keklik
- Cem SahinCSCem Sahin
- Oğuz G. YildizOYOğuz G. Yildiz
- Selahattin MentesSMSelahattin Mentes
- Fatih KurnazFKFatih Kurnaz
- Dicle AslanDADicle Aslan
- Serdar SivginSSSerdar Sivgin
- Serdar SoyuerSSSerdar Soyuer
- Bülent EserBEBülent Eser
- 1 February 2015
- journal article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 38 (1) , 68-73
Abstract
To assess the outcomes of overall survival and posttransplantation survival in patients with Hodgkin lymphoma (HL) undergoing autologous stem cell transplantation (ASCT) because of the development of relapse or resistance after chemotherapy (CT) or CT plus radiotherapy (combined modality treatment, CMT). Forty-five patients undergoing ASCT because of the development of relapse or resistance after CT or CMT for HL were enrolled in the study. Radiotherapy was given as involved-field radiotherapy. Patients were treated with CT alone (n=25) or CMT (n=20). These 2 groups were further divided into 2 subgroups: the patients with early-stage (I to II) and advanced-stage (III to IV) HL. Median patients age was 29 years (range, 16 to 60 y) and the median follow-up was 60 months (range, 12 to 172 mo). In the patients with advanced-stage HL, there was no statistically significant difference in overall survival between irradiated and nonirradiated patients (n=18, irradiated n=4 and nonirradiated n=14). However, in the patients with early-stage disease, there was a significant difference in 5- and 10-year overall survival between the irradiated and nonirradiated groups (81% vs. 48% and 66% vs. 24%, respectively, P=0.045; n=26, irradiated n=16 and nonirradiated n=10). In the univariate analysis, irradiated group and involvement of 1 to 2 nodal regions were found to be significant for overall survival, whereas irradiated group, early stage, and involvement of 1 to 2 nodal regions were found to be significant for posttransplantation survival. However, only irradiated group was found to be significant for posttransplantation survival in multivariate analysis (P<0.05). Addition of involved-field radiotherapy to CT in patients undergoing ASCT after relapse or recurrence failed to provide survival benefit in patients with advanced HL, while a survival benefit was observed in patients with early-stage HL. Radiotherapy should be considered as part of CMT in the patients with early-stage HL, which should not be neglected.Keywords
This publication has 24 references indexed in Scilit:
- Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationHaematologica, 2011
- Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphomaBone Marrow Transplantation, 2008
- State-of-the-Art Therapeutics: Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Long term follow up in relapsed Hodgkin’s disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT)Journal of Clinical Oncology, 2005
- Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's diseaseBritish Journal of Haematology, 2004
- Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical TrialJournal of Clinical Oncology, 2002
- Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant RegistryJournal of Clinical Oncology, 1999
- Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.Journal of Clinical Oncology, 1998
- High-dose therapy and autologous bone marrow transplantation for relapsed/refractory hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survivalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's diseaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995